2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1709

Juvenile-Onset IgG4-Related Disease: A Systematic Review
Abstract Number: 1710

Chemokine and Cytokine Tear Profile of Patients with IgG4-Related Disease
Abstract Number: 1711

Distinctive Imaging Features Between IgG4-Related Ophthalmic Disease and Graves’ Orbitopathy: A Comparative Study
Abstract Number: 1712

Head and Neck Involvement of IgA Vasculitis: A Case-Control Study
Abstract Number: 1713

Drug-induced IgA Vasculitis: Data from the French Pharmacovigilance Network and the WHO VigiBase
Abstract Number: 1714

Can We Predict Early Relapses in Adult IgA Vasculitis?
Abstract Number: 1715

Predictors of Gastrointestinal and Renal Involvement in Adult IgA Vasculitis
Abstract Number: 1716

Poor-Prognosis Factors of Systemic Vasculitides with Gastrointestinal Involvement: Data from a Large Retrospective Study
Abstract Number: 1717

Identifying Patterns of Histopathologic Presentation in CNS Vasculitis
Abstract Number: 1718

Geographic Disparities in Mortality Rates of Vasculitis in the United States: 1999 to 2017
Abstract Number: 1719

Clinical Phenotypes in Relapsing Polychondritis in a Prospective Cohort
Abstract Number: 1720

Pentoxifylline Gel for Oral Ulcers in Patients with Behçet’s Syndrome
Abstract Number: 1721

Adult Primary Central Nervous System Vasculitis Treatment and Course: A Long-term Follow-up Study
Abstract Number: 1722

Mixed Cryoglobulin Immune Complex Proteomics: Analysis by Mass Spectroscopy
Abstract Number: 1723

Mixed Cryoglobulinaemia Since the Advent of New Direct-acting Antivirals for Hepatitis C Infection: Clinical Characteristics, Etiologies and Biological Features in 679 Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].